摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-n-butylpiperazine | 90203-03-5

中文名称
——
中文别名
——
英文名称
2-n-butylpiperazine
英文别名
2-Butyl-piperazin;2-butyl-piperazine;2-Butylpiperazine
2-n-butylpiperazine化学式
CAS
90203-03-5
化学式
C8H18N2
mdl
MFCD19219095
分子量
142.244
InChiKey
CTEGAXWZJISNOR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    115-118 °C(Press: 12 Torr)
  • 密度:
    0.841±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    10
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    24.1
  • 氢给体数:
    2
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    2-n-butylpiperazine盐酸三乙胺 作用下, 以 二氯甲烷丙酮 为溶剂, 反应 6.0h, 生成 2-Butyl-1-(toluene-4-sulfonyl)-piperazine; hydrochloride
    参考文献:
    名称:
    血小板活化因子(PAF)中的构效关系。11从PAF拮抗作用到磷脂酶A(2)抑制:1-芳基磺酰胺基-2-烷基哌嗪的合成与结构活性关系。
    摘要:
    1-苄基-2-烷基哌嗪是I和II组分泌的PLA(2)s的强抑制剂。通过用磺酰胺取代酰胺官能团并通过在苯磺酰基部分的对位引入电子给体取代基,可以提高其活性。哌嗪环的一个碳原子上的位置或该碳原子的绝对构型都不会影响对PLA(2)的一个或另一个基团的亲和力,但亲脂性对于这些系列仍然是必不可少的参数。此外,结构活性关系允许这些哌嗪衍生物与PLA(2)s催化位点相互作用的新假设。
    DOI:
    10.1016/s0223-5234(01)01274-0
  • 作为产物:
    描述:
    6-Butyl-1,2,3,6-tetrahydropyrazine 在 氢气 作用下, 以 乙醇 为溶剂, 反应 72.0h, 以to yield 2-butylpiperazine (0.8 g, 5.63 mmol) as a yellow solid的产率得到2-n-butylpiperazine
    参考文献:
    名称:
    Piperazines as P2X7 antagonists
    摘要:
    化合物I式的新型化合物或其药学上可接受的盐、代谢物、异构体、对映体或前药,其中取代基如本文所定义,这些化合物可用作治疗剂。
    公开号:
    US20080076924A1
点击查看最新优质反应信息

文献信息

  • N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES
    申请人:GRIFFIOEN Gerard
    公开号:US20100197703A1
    公开(公告)日:2010-08-05
    This invention provides thiazolylpiperazine derivatives, and N-sulfonyl heterocyclic derivatives including phenyl- and benzyl-thiazolylpiperidine derivatives, and pharmaceutically acceptable salts thereof, which are useful active ingredients for administration in a method for the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides methods for making such derivatives, and pharmaceutical compositions including such derivatives together with pharmaceutically acceptable excipients.
    该发明提供了噻唑哌嗪生物,以及包括苯基和苄基噻唑哌啶生物的N-磺酰杂环衍生物,以及其药学上可接受的盐,这些是用于治疗α-突触核蛋白病的有效活性成分,如帕森病、弥漫性小体病、创伤性脑损伤、肌萎缩侧索硬化症、尼曼-匹克病、哈勒沃登-施帕茨综合征、唐氏综合征、神经轴突萎缩、多系统萎缩和阿尔茨海默病的治疗方法。该发明还提供了制备这些衍生物的方法,以及包括这些衍生物和药学上可接受的辅料的药物组合物。
  • Isoquinolinesulfonyl derivatives and process for the preparation thereof
    申请人:Asahi Kasei Kogyo Kabushiki Kaisha
    公开号:EP0061673A1
    公开(公告)日:1982-10-06
    A 5-isoquinolinesulfonyl derivative of Formula (I): wherein f is zero or one; m and n each is an integer of one to nine; m+n is an integer of at least one; R1 is a hydrogen atom, a C1-10 alkyl group, a C5-6cycloalkyl group or an aryl group; or R2 and R3 each is a hydrogen atom, a C1-10 alkyl group, a C5-6 cycloalkyl group, an aryl group or an aralkyl group; R2 and R3 are C1-6 alkylene groups and linked directly or through an oxygen atom to form a 5- to 7-membered heterocyclic ring with the adjacent nitrogen atom; or the group is a group wherein R4 and Rs each is a hydrogen atom, a C1-10 alkyl group, an aryl group or an aralkyl group and R6 is a hydrogen atom, a C1-10 alkyl group, an aryl group, an aralkyl group, a benzoyl group, a cinnamyl group, a cinnamoyl group, a furoyl group or a group wherein R, is a C1-8 alkyl group, and the pharmaceutically acceptable salt thereof; and a process for the preparation thereof. The compounds of this invention have a relaxatory action for vascular smooth muscle and are useful as a vasodilator and a hypotensor.
    式(I)的 5-异喹啉磺酰基衍生物: 其中 f 为零或一 m 和 n 均为一至九的整数 m+n 至少为 1 的整数; R1 是氢原子、C1-10 烷基、C5-6 环烷基或芳基;或 R2 和 R3 各为氢原子、C1-10 烷基、C5-6 环烷基、芳基或芳烷基; R2 和 R3 为 C1-6 烯基,直接或通过氧原子连接,与相邻的氮原子形成 5-7 元杂环;或 基团为 其中 R4 和 Rs 分别为氢原子、C1-10 烷基、芳基或芳烷基,R6 为氢原子、C1-10 烷基、芳基、芳烷基、苯甲酰基、肉桂酰基、肉桂酰基、呋喃基或 其中 R 是 C1-8 烷基的基团及其药学上可接受的盐;以及其制备方法。本发明的化合物对血管平滑肌具有松弛作用,可用作血管扩张剂和降压剂。
  • Use of a catalyst in epoxy compositions
    申请人:THE DOW CHEMICAL COMPANY
    公开号:EP0328020A2
    公开(公告)日:1989-08-16
    Storage stable compositions are disclosed which comprise an epoxide containing compound, a phenolic hydroxyl containing compound, and a catalyst compound for catalyzing the reaction between epoxide groups and aromatic hydroxyl groups which catalyst comprises the product resulting from contacting an onium compound, non-heterocyclic amine compound, heterocyclic nitrogen compound or salt thereof with an acid or a salt of an acid having a weak nucleophilic anion.
    本发明公开了一种贮存稳定的组合物,该组合物包括一种含环氧化物的化合物、一种含羟基的化合物和一种催化环氧化物基团与芳香羟基基团反应的催化剂化合物,该催化剂包括鎓化合物、非杂环胺化合物、杂环氮化合物或其盐与酸或具有弱亲核阴离子的酸的盐接触后产生的产物。
  • Latent catalysts, cure-inhibited epoxy resin compositions and laminates prepared therefrom
    申请人:THE DOW CHEMICAL COMPANY
    公开号:EP0458502A2
    公开(公告)日:1991-11-27
    In summary, the application is related to the discovery of a class of compounds which comprises boric acid or maleic acid or a mixture of boric acid with at least one acid having a weak nucleophilic anion, which inhibits the reaction of a polyepoxide with a curing agent at low temperatures. In another embodiment the application is a latent catalyst system adapted for curing a polyepoxide resulting from contacting I) a catalyst for the cure of a polyepoxide compound comprising an amine, heterocyclic nitrogen phosphine, sulfide, phosphine, sulfide, ammonium, phosphonium, sulfonium, arsonium, containing compound or a mixture thereof; with II) boric acid, or a mixture of boric acid with at least an acid having a weak nucleophilic anion. Further the application relates to epoxy resin compositions containing the inhibitor or latent catalytic composition. In still another embodiment the application relates to a composition useful for curing a polyepoxide which contains: A) an inhibiting amount of boric acid or maleic acid or a mixture of boric acid with at least one acid having a weak nucleophilic anion; and optionally B) a catalytic amount of a catalyst useful for accelerating the reaction of a polyepoxide with the curing agent, wherein the inhibitor and catalyst may be present in complex form.
    总之,本申请涉及一类化合物的发现,该化合物由硼酸马来酸硼酸与至少一种具有弱亲核阴离子的酸的混合物组成,在低温下可抑制聚环氧化物与固化剂的反应。在另一个实施方案中,本申请涉及一种潜伏催化剂系统,该系统适用于固化聚环氧乙烷,该固化聚环氧乙烷化合物的催化剂包括胺、杂环含氮膦、硫化物、膦、硫化物、锍、胂、含化合物或其混合物;与 I) 硼酸硼酸与至少一种具有弱亲核阴离子的酸的混合物接触后产生的聚环氧乙烷。此外,本申请还涉及含有抑制剂或潜在催化成分的环氧树脂组合物。在另一个实施方案中,本申请涉及一种用于固化聚环氧树脂的组合物,该组合物含有A) 抑制量的硼酸马来酸硼酸与至少一种具有弱亲核阴离子的酸的混合物;以及 B) 催化量的催化剂,用于加速聚环氧化物与固化剂的反应,其中抑制剂和催化剂可以复合物形式存在。
  • Catalysts and epoxy resin composition containing the same
    申请人:THE DOW CHEMICAL COMPANY
    公开号:EP0553887A2
    公开(公告)日:1993-08-04
    Storage stable compositions are disclosed which comprise an epoxide containing compound, a phenolic hydroxyl containing compound, and a catalyst compound for catalyzing the reaction between epoxide groups and aromatic hydroxyl groups which catalyst comprises the product resulting from contacting an onium compound, non-heterocyclic amine compound, heterocyclic nitrogen compound or salt thereof with an acid or a salt of an acid having a weak nucleophilic anion.
    本发明公开了一种贮存稳定的组合物,该组合物包括一种含环氧化物的化合物、一种含羟基的化合物和一种催化环氧化物基团与芳香羟基基团反应的催化剂化合物,该催化剂包括鎓化合物、非杂环胺化合物、杂环氮化合物或其盐与酸或具有弱亲核阴离子的酸的盐接触后产生的产物。
查看更多